Ratings by Credit Suisse (Jonathan Yong)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
8/15/2023 | Definitive Healthcare Corp | DH | Maintain | Neutral (N/A) |
|
Details | ||
8/11/2023 | GoHealth Inc. | GOCO | Maintain | Underperform (N/A) |
|
Details | ||
8/10/2023 | GoodRx Holdings Inc. | GDRX | Maintain | Neutral (N/A) |
|
Details | ||
8/9/2023 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
6/30/2023 | Accolade Inc. | ACCD | Maintain | Neutral (N/A) |
|
Details | ||
5/10/2023 | eHealth | EHTH | Maintain | Neutral (N/A) |
|
Details | ||
5/10/2023 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
5/5/2023 | Definitive Healthcare Corp | DH | Maintain | Neutral (N/A) |
|
Details | ||
4/25/2023 | Accolade Inc. | ACCD | Maintain | Neutral (N/A) |
|
Details | ||
4/4/2023 | GoHealth Inc. | GOCO | Maintain | Underperform (N/A) |
|
Details | ||
3/6/2023 | Clover Health | CLOV | Maintain | Underperform (N/A) |
|
Details | ||
3/6/2023 | eHealth | EHTH | Maintain | Neutral (N/A) |
|
Details | ||
3/2/2023 | GoodRx Holdings Inc. | GDRX | Maintain | Neutral (N/A) |
|
Details | ||
2/28/2023 | Hims and Hers | HIMS | Maintain | Outperform (N/A) |
|
Details | ||
2/24/2023 | Definitive Healthcare Corp | DH | Maintain | Neutral (N/A) |
|
Details | ||
2/21/2023 | Selectquote | SLQT | Maintain | Neutral (N/A) |
|
Details | ||
2/10/2023 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
11/4/2022 | Definitive Healthcare Corp | DH | Maintain | Neutral (N/A) |
|
Details | ||
10/7/2022 | Accolade Inc. | ACCD | Maintain | Neutral (N/A) |
|
Details | ||
8/16/2022 | GoHealth Inc. | GOCO | Maintain | Underperform (N/A) |
|
Details | ||
8/15/2022 | eHealth | EHTH | Maintain | Neutral (N/A) |
|
Details | ||
8/10/2022 | Hims and Hers | HIMS | Maintain | Outperform (N/A) |
|
Details | ||
8/9/2022 | GoodRx Holdings Inc. | GDRX | Maintain | Neutral (N/A) |
|
Details | ||
8/9/2022 | Clover Health | CLOV | Maintain | Underperform (N/A) |
|
Details | ||
5/31/2022 | Change Healthcare Inc. | CHNG | Maintain | Neutral (N/A) |
|
Details | ||
5/11/2022 | Hims and Hers | HIMS | Maintain | Outperform (N/A) |
|
Details | ||
5/10/2022 | GoodRx Holdings Inc. | GDRX | Maintain | Neutral (N/A) |
|
Details | ||
5/4/2022 | eHealth | EHTH | Maintain | Neutral (N/A) |
|
Details | ||
4/29/2022 | Accolade Inc. | ACCD | Downgrade | Neutral (Outperform) |
12.28 (9.40) |
-23.45% | Details | |
4/1/2022 | Selectquote | SLQT | New Coverage | Neutral (N/A) |
2.90 (1.60) |
-44.83% | Details | |
4/1/2022 | Hims and Hers | HIMS | New Coverage | Outperform (N/A) |
5.32 (12.34) |
131.95% | Details | |
4/1/2022 | GoHealth Inc. | GOCO | New Coverage | Underperform (N/A) |
1.21 (10.05) |
730.58% | Details | |
4/1/2022 | GoodRx Holdings Inc. | GDRX | New Coverage | Neutral (N/A) |
18.96 (6.96) |
-63.29% | Details | |
4/1/2022 | eHealth | EHTH | New Coverage | Neutral (N/A) |
12.46 (4.52) |
-63.72% | Details | |
4/1/2022 | Definitive Healthcare Corp | DH | New Coverage | Neutral (N/A) |
23.90 (7.25) |
-69.67% | Details | |
4/1/2022 | Change Healthcare Inc. | CHNG | New Coverage | Neutral (N/A) |
21.89 (27.49) |
25.58% | Details | |
4/1/2022 | Accolade Inc. | ACCD | New Coverage | Outperform (N/A) |
17.98 (9.40) |
-47.72% | Details | |
1/7/2022 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
1/7/2022 | Clover Health | CLOV | Downgrade | Underperform (Neutral) |
3.58 (0.65) |
-81.84% | Details | |
11/15/2021 | Clover Health | CLOV | Maintain | Neutral (N/A) |
|
Details | ||
11/11/2021 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
11/3/2021 | Clover Health | CLOV | Maintain | Neutral (N/A) |
|
Details | ||
9/20/2021 | Oscar Health Inc | OSCR | Maintain | Outperform (N/A) |
|
Details | ||
9/2/2021 | Oscar Health Inc | OSCR | New Coverage | Outperform (N/A) |
15.59 (17.59) |
12.83% | Details | |
9/2/2021 | Clover Health | CLOV | New Coverage | Neutral (N/A) |
8.58 (0.65) |
-92.42% | Details |